Multicenter Analysis of Valganciclovir Prophylaxis in Pediatric Solid Organ Transplant Recipients
Authors:
- Marc FocaMFMarc Foca
- Salih DemirhanSDSalih Demirhan
- Flor M MunozFMFlor M Munoz
- Kristen G Valencia DerayKDKristen G Valencia Deray
- Claire E BocchiniCBClaire E Bocchini
- Tanvi S SharmaTSTanvi S Sharma
- Gilad ShermanGSGilad Sherman
- William J MullerWMWilliam J Muller
- Taylor Heald-SargentTHTaylor Heald-Sargent
- Lara Danziger-IsakovLDLara Danziger-Isakov
- Juri BoguniewiczJBJuri Boguniewicz
Open Access
- 28 June 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (7) , ofae353
Abstract
Valganciclovir is the only approved antiviral for cytomegalovirus (CMV) prevention in pediatric solid organ transplantation (SOT). Additional approaches may be needed to improve outcomes. A multicenter retrospective study from 2016 to 2019 was conducted of pediatric SOT recipients in whom at least 3 months of valganciclovir prophylaxis was planned. Episodes of CMV DNA in blood (DNAemia), CMV disease, drug-related toxicities, as well as other infections in the first year posttransplant and demographic and clinical data were collected. CMV DNAemia in the first year after prophylaxis or during prophylaxis (breakthrough) was analyzed by multivariate hazard models. Among the 749 patients enrolled, 131 (17.5%) had CMV DNAemia at any time in the first year; 85 (11.4%) had breakthrough DNAemia, and 46 (6.1%) had DNAemia after prophylaxis. CMV disease occurred in 30 (4%). In a multivariate model, liver transplantation compared to kidney or heart, intermediate or high risk based on donor/recipient serologies, neutropenia, and valganciclovir dose modifications attributed to toxicity were associated with increased risk of total and/or breakthrough DNAemia. Bacteremia was also associated with increased hazard ratio for CMV DNAemia. In a separate multivariate analysis, rejection occurred more often in those with breakthrough CMV DNAemia (P = .002); liver transplants, specifically, had increased rejection if CMV DNAemia occurred in the first year (P = .004). These associations may be bidirectional as rejection may contribute to infection risk. CMV DNAemia in the first year posttransplantation occurs despite valganciclovir prophylaxis and is associated with medication toxicity, bacteremia, and rejection. Pediatric studies of newer antivirals, especially in higher-risk subpopulations, appear to be warranted.Keywords
Funding Information
- Merck & Co
This publication has 38 references indexed in Scilit:
- A Hybrid Strategy for the Prevention of Cytomegalovirus-Related Complications in Pediatric Liver Transplantation RecipientsTransplantation, 2009
- Valganciclovir for Cytomegalovirus Prevention in Solid Organ Transplant Patients: An Evidence-Based Reassessment of Safety and EfficacyPLOS ONE, 2009
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- Infectious Complications of Antilymphocyte Therapies in Solid Organ TransplantationClinical Infectious Diseases, 2009
- Cytomegalovirus Prophylaxis and Graft Outcome in Solid Organ Transplantation: A Collaborative Transplant Study ReportAmerican Journal of Transplantation, 2004
- Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant RecipientsAmerican Journal of Transplantation, 2004
- A Safety Study of Oral Valganciclovir Maintenance Treatment of Cytomegalovirus RetinitisJAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
- A Controlled Trial of Valganciclovir as Induction Therapy for Cytomegalovirus RetinitisNew England Journal of Medicine, 2002
- Role of cytomegalovirus infection in allograft rejection: a review of possible mechanismsTransplant Immunology, 1999
- ORAL GANCICLOVIR DOSING IN TRANSPLANT RECIPIENTS AND DIALYSIS PATIENTS BASED ON RENAL FUNCTION1Transplantation, 1998